Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.45-0.25 (-3.73%)
At close: 04:00PM EST
6.45 0.00 (0.00%)
After hours: 06:38PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close6.70
Open6.55
Bid6.41 x 1300
Ask6.42 x 800
Day's Range6.33 - 6.70
52 Week Range4.21 - 22.22
Volume517,655
Avg. Volume818,693
Market Cap423.681M
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.32
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CDXS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Codexis, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Simply Wall St.

    Codexis (NASDAQ:CDXS) shareholders have endured a 68% loss from investing in the stock a year ago

    Over the last month the Codexis, Inc. ( NASDAQ:CDXS ) has been much stronger than before, rebounding by 41%. But that's...

  • GlobeNewswire

    Codexis Announces Appointment of Sri Ryali as Chief Financial Officer

    REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company’s financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. “I am ex

  • GlobeNewswire

    Codexis Announces Appointment of H. Stewart Parker to Board of Directors

    REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background,

Advertisement
Advertisement